Literature DB >> 15098809

Tegaserod-induced myocardial infarction: case report and hypothesis.

Anthony J Busti1, Jose R Murillo, Byron Cryer.   

Abstract

Serotonin (5-hydroxytryptamine [5-HT])1 receptor agonists, such as those used for treating migraine, can cause coronary artery contraction, coronary spasm, and even myocardial infarction. Tegaserod maleate is a relatively new 5-HT4 receptor agonist with moderate affinity for the 5-HT1 receptor. Currently, it is approved only for treatment of irritable bowel syndrome in women who have constipation as the primary symptom. However, it is also being administered as a promotility agent in patients with gastroparesis. Since tegaserod has affinity for the 5-HT1 receptor, it is plausible that tegaserod could cause the same types of cardiovascular adverse events seen with agents prescribed for management of migraine. We report the first case of a man who experienced a myocardial infarction after receiving only two 6-mg doses of tegaserod; we also provide a hypothesis regarding this event. When considering prescribing a drug with 5-HT1 receptor agonist activity, clinicians should review the patient's medical history specifically for the presence of underlying cardiovascular risk factors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15098809     DOI: 10.1592/phco.24.5.526.33351

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  18 in total

1.  The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity.

Authors:  J A M Smith; D T Beattie; D Marquess; J P Shaw; R G Vickery; P P A Humphrey
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-04-16       Impact factor: 3.000

Review 2.  Bloating and functional gastro-intestinal disorders: where are we and where are we going?

Authors:  Paola Iovino; Cristina Bucci; Fabrizio Tremolaterra; Antonella Santonicola; Giuseppe Chiarioni
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

3.  Prucalopride-associated acute tubular necrosis.

Authors:  Vithika Sivabalasundaram; Flavio Habal; David Cherney
Journal:  World J Clin Cases       Date:  2014-08-16       Impact factor: 1.337

Review 4.  Early life risk factors that contribute to irritable bowel syndrome in adults: a systematic review.

Authors:  Denesh K Chitkara; Miranda A L van Tilburg; Nannette Blois-Martin; William E Whitehead
Journal:  Am J Gastroenterol       Date:  2008-01-02       Impact factor: 10.864

Review 5.  Prokinetics in the Management of Functional Gastrointestinal Disorders.

Authors:  Eamonn M M Quigley
Journal:  Curr Gastroenterol Rep       Date:  2017-09-08

Review 6.  New Options in Constipation Management.

Authors:  Mellar Davis; Pamela Gamier
Journal:  Curr Oncol Rep       Date:  2015-12       Impact factor: 5.075

7.  Aqueous extracts of Liriope platyphylla induced significant laxative effects on loperamide-induced constipation of SD rats.

Authors:  Ji Eun Kim; Young Ju Lee; Moon Hwa Kwak; Jun Ko; Jin Tae Hong; Dae Youn Hwang
Journal:  BMC Complement Altern Med       Date:  2013-11-26       Impact factor: 3.659

Review 8.  Diagnosis and treatment of chronic constipation--a European perspective.

Authors:  J Tack; S Müller-Lissner; V Stanghellini; G Boeckxstaens; M A Kamm; M Simren; J-P Galmiche; M Fried
Journal:  Neurogastroenterol Motil       Date:  2011-05-24       Impact factor: 3.598

Review 9.  Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders.

Authors:  J Tack; M Camilleri; L Chang; W D Chey; J J Galligan; B E Lacy; S Müller-Lissner; E M M Quigley; J Schuurkes; J H De Maeyer; V Stanghellini
Journal:  Aliment Pharmacol Ther       Date:  2012-02-22       Impact factor: 8.171

10.  Cellular mechanisms underlying the laxative effect of flavonol naringenin on rat constipation model.

Authors:  Zi-Huan Yang; Hai-Jie Yu; Ao Pan; Jian-Yang Du; Ye-Chun Ruan; Wing-Hung Ko; Hsiao-Chang Chan; Wen-Liang Zhou
Journal:  PLoS One       Date:  2008-10-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.